At the news
? BEARISHIMPACT 4/10 CLUSTER filed Sep 1, 2026 at 18:36 ET
Oruka Therapeutics CEO Lawrence Klein and COO Laura Sandler sold a combined $5.94M in open-market stock on September 1, 2026. While the CEO's sales are partly explained by cashless derivative exercises at $7.80 strike (pre-funded near 100% profit), the $5.84M CEO sale is large relative to market cap (0.1%). The net selling direction and C-suite participation merit attention, though the size is modest as a percentage of market cap (<0.1%), keeping the signal below the materiality threshold.
- CEO Lawrence Klein sold 75,000 shares total (6.6K + 4.8K + 63.6K) in open-market sales for ~$6.89M, all on 2026-09-01
- CEO also exercised two derivative tranches: 75,000 shares at $7.80 ($585K exercise) and 75,000 shares at $0 (non-cash award)
- COO Laura Sandler sold 5,000 shares total for ~$459K on 2026-09-01 after exercising 5,000 at $7.80 and 5,000 at $0
- Combined open-market sales: CEO $6.89M + COO $459K = $7.35M total; net cluster value after derivative exercises: $5.94M
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access